Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cortexyme, Inc. stock logo
CRTX
Cortexyme
$1.61
-1.2%
$1.64
$1.78
$40.66
$48.54M1.4620,672 shs61,949 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$13.48
+12.1%
$12.77
$10.15
$15.85
$21.65M1.192,237 shs15,888 shs
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$1.99
+13.7%
$1.40
$7.80
$12.38
$34.33MN/A41,322 shs837,649 shs
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
$0.73
+0.8%
$3.47
$0.50
$2.67
$12.56M1.833.78 million shs128,718 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cortexyme, Inc. stock logo
CRTX
Cortexyme
+1.24%-5.23%-14.21%+49.54%+154.69%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
+12.05%+5.81%+8.80%+3.69%+22.10%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
+1.16%+10.06%+1.74%+68.27%-50.70%
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
-7.15%-11.21%-23.99%-4.84%-79.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/AN/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/AN/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cortexyme, Inc. stock logo
CRTX
Cortexyme
0.00
N/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00
N/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
0.00
N/AN/AN/A
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/A$3.97 per shareN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/A$14.25 per shareN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/A$0.07 per share27.08($0.53) per shareN/A
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
$10K1,255.69N/AN/A$1.33 per share0.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cortexyme, Inc. stock logo
CRTX
Cortexyme
-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-$74.75M-$8.82N/AN/AN/A-69.14%-26.92%N/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$6.85MN/A0.00N/AN/A-49.58%2.84%N/A
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
-$8.35MN/A0.00N/A-230.34%-122.20%-110.61%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/A
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/A
9.92
9.92
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/A
3.87
3.87
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/A
0.15
0.15
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
N/A
14.96
14.96

Institutional Ownership

CompanyInstitutional Ownership
Cortexyme, Inc. stock logo
CRTX
Cortexyme
63.18%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
21.77%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
47.97%
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
5.24%

Insider Ownership

CompanyInsider Ownership
Cortexyme, Inc. stock logo
CRTX
Cortexyme
27.90%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
44.90%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
20.00%
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
2.11%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cortexyme, Inc. stock logo
CRTX
Cortexyme
5530.15 million21.74 millionNot Optionable
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1901.61 million885,000No Data
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
317.25 million13.80 millionNot Optionable
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
717.30 millionN/ANot Optionable

Recent News About These Companies

Seneca, SC Weather Conditions
Seneca Park Zoo announces death of Canada lynx
4 Bedroom Home in Seneca Falls - $499,000
Seneca Foods Corp Class A
Seneca, Schuyler Thruway service areas reopen with upgraded facilities
Seneca Park Zoo welcomes new 2-year-old giraffe. See the photos
‘The Show’ @ Shea’s Seneca
Done Deal: Highmark Moving to Seneca One
Better Look: Seneca One Plans
West Seneca West Senior High School
Seneca High School
St. Patrick's Day Music Fest in West Seneca

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cortexyme stock logo

Cortexyme NASDAQ:CRTX

$1.61 -0.02 (-1.23%)
As of 08/21/2025

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Finch Therapeutics Group stock logo

Finch Therapeutics Group NASDAQ:FNCH

$13.48 +1.45 (+12.05%)
As of 08/21/2025 03:58 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

JATT Acquisition stock logo

JATT Acquisition NYSE:JATT

$1.99 +0.24 (+13.71%)
As of 08/21/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

Seneca Biopharma stock logo

Seneca Biopharma NASDAQ:SNCA

Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, develops novel treatments for diseases of high unmet medical needs. The company's stem cell-based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury; and NSI-189 that has completed Phase II clinical trials for the treatment of major depressive disorder. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.